BioSpace News Archive

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced topline data from SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, Enanta’s oral, 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.

Certara, Inc., a global leader in biosimulation, reported its financial results for the first quarter of fiscal year 2023.

Dynavax Technologies Corporation, a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, announced that the Company will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, at 1:00 p.m. E.T.

McKesson Corporation has released its fiscal 2023 fourth-quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended March 31, 2023.

Navidea Biopharmaceuticals, Inc. announced the introduction of a Fix, Fund, Propel approach to driving the Company’s strategy forward; The Company will issue a press release detailing financial highlights and corporate developments in lieu of hosting conference call and webcast for the first quarter ended March 31st, 2023.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2023.

Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2023.

ICU Medical, Inc., a leader in the development, manufacture and sale of innovative medical products, announced financial results for the quarter ended March 31, 2023.